advertisement
Abstract #3622 Published in IGR 4-2
A multicenter evaluation on the additive effect of nipradilol ophthalmic solution
Nakagawa T; Takahashi T; Saie T; Araki H; Takei A; Yui A; Tachibana N; Kimura T; Kanai AJapanese Journal of Clinical Ophthalmology 2002; 56: 355-360
The authors prospectively evaluated the additive or replacement effect of nipradilol ophthalmic solution in 88 eyes of 52 patients. Six institutions participated in the program. The cases comprised open-angle glaucoma (50 eyes), normal-tension glaucoma (19 eyes), and ocular hypertension (19 eyes). All the cases had been treated by beta-blocker, carbonic anhybrase inhibitor, or prostaglandins, with insufficient hypotensive effect. The intraocular pressure (IOP) averaged 18.1 ± 0.2 mmHg (mean ± SD) initially and 16.8 ± 0.3 mmHg two or three months after initiation of nipradilol. The difference was significant (p < 0.001). The hypotensive effect was most pronounced when beta-blocker was replaced by nipradilol, with the IOP averaging 18.4 ± 0.4 mmHg initially and 16.8 ± 0.3 mmHg after nipradilol (p < 0.001). There were no significant changes in pulse rate, blood pressure or quantity of lacrimal fluid throughout. LA: Japanese
Dr. T. Nakagawa, Department of Ophthalmology, Koshigaya Municipal Hospital, 10-47-1 Higashi, Koshigaya-shi 343-0023, Japan
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
